Evolent Health (EVH) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.06
- Estimate
- $0.06
- Surprise
- —
- Revenue (period 2026-09-30)
- $725.4M
- Score today
- 5.7/10
Revenue source: xbrl.
How the report landed
Evolent Health (EVH) reported adjusted EPS of $0.06, in line with the $0.06 estimate.
Coverage in the report window
- Needham Maintains Buy Rating and Raises Price Target for Evolent Health — fiscal.ai, 2026-11-06
- Evolent Health, Inc. Announces Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-05
- Needham Maintains Buy on Evolent Health, Raises Price Target to $6 — benzinga, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates EVH Sell at 5.7/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate.
What argues against it
- Quality below floor (1.7 < 4.0)
- Momentum score 3.2/10 — below 4.5 minimum
- Reward/Risk 0.7:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.53
- Price target
- $5.00
- Stop
- $4.21
- Upside to target
- +10.5%
- Reward-to-risk
- 0.7:1
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
EVH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Health Information Services
- Market cap
- $513.3M
- P/E (fwd)
- 11.2
- 52-week range
- $2.10–$6.33
- Off 52-week high
- 28.6%
- RSI (14)
- 51
- Volume vs avg
- 0.41×
- Score today
- 5.7/10